Around the Practice June 23, 2021: Genomic and Genetic Testing in Prostate Cancer

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, explains the increased significance of genomic testing in the field of prostate cancer.

Brian T. Helfand, MD, PhD, discusses how the precision of genomic testing data can alleviate the accuracy issues associated with PSA testing for screening and monitoring prostate cancer.

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses how genomic testing is a great tool for identifying “what is going on in the tumor ‘right now.’”

Brian T. Helfand, MD, PhD, NorthShore University HealthSystem, discusses the value of using multiparametric MRI and genomic testing together when making treatment decisions in prostate cancer.